Literature DB >> 17700598

Prolonged anorexia and elevated plasma cytokine levels following myeloablative allogeneic hematopoietic cell transplant.

F R Malone1, W M Leisenring, B E Storer, R Lawler, J M Stern, S N Aker, M E Bouvier, P J Martin, A L Batchelder, H G Schoch, G B McDonald.   

Abstract

Myeloablative conditioning regimens commonly lead to prolonged anorexia and poor oral intake. In a prospective study of 147 patients receiving CY, total body irradiation and allogeneic hematopoietic cells, we determined the extent of decline in oral intake and assessed plasma cytokine levels and development of acute GVHD as explanations for protracted anorexia. For each patient, daily oral caloric intake was expressed as a percent of estimated basal requirements, calculated as basal energy expenditure, through day 20. Oral caloric intake was significantly reduced in 92% of patients and remained low. The nadir in oral intake occurred at days 10-12, when median oral caloric intake was 3% of basal energy requirements. Plasma cytokines known to affect appetite (IL2, IL6, tumor necrosis factor-alpha) were significantly elevated above normal following conditioning therapy (P<0.001 for each cytokine). Acute GVHD did not appear to affect oral intake to transplant day 20 in this cohort of patients; however, plasma levels of IL6 rose steeply before the clinical onset of GVHD. Persistent fever occurred with the greatest frequency in patients with most profound reduction in oral intake. We conclude that prolonged alterations in oral intake following this myeloablative regimen may be related to circulating cytokines known to alter eating behavior.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17700598     DOI: 10.1038/sj.bmt.1705816

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  16 in total

1.  Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease.

Authors:  George B McDonald; Laura Tabellini; Barry E Storer; Paul J Martin; Richard L Lawler; Steven L Rosinski; H Gary Schoch; John A Hansen
Journal:  Biol Blood Marrow Transplant       Date:  2017-05-03       Impact factor: 5.742

Review 2.  Pleiotropic effects of transforming growth factor-β in hematopoietic stem-cell transplantation.

Authors:  Stephanie M Coomes; Bethany B Moore
Journal:  Transplantation       Date:  2010-12-15       Impact factor: 4.939

Review 3.  Discovery and validation of graft-versus-host disease biomarkers.

Authors:  Sophie Paczesny
Journal:  Blood       Date:  2012-11-19       Impact factor: 22.113

Review 4.  Revisiting nutritional support for allogeneic hematologic stem cell transplantation-a systematic review.

Authors:  A Baumgartner; A Bargetzi; N Zueger; M Bargetzi; M Medinger; L Bounoure; F Gomes; Z Stanga; B Mueller; P Schuetz
Journal:  Bone Marrow Transplant       Date:  2017-01-09       Impact factor: 5.483

Review 5.  Prevention and Treatment of Acute Graft-versus-Host Disease in Children, Adolescents, and Young Adults.

Authors:  Erin Gatza; Pavan Reddy; Sung Won Choi
Journal:  Biol Blood Marrow Transplant       Date:  2020-01-11       Impact factor: 5.742

Review 6.  Graft-versus-host disease biomarkers: omics and personalized medicine.

Authors:  Sophie Paczesny; Nisha Raiker; Sam Brooks; Christy Mumaw
Journal:  Int J Hematol       Date:  2013-09       Impact factor: 2.490

7.  Urinary elafin and kidney injury in hematopoietic cell transplant recipients.

Authors:  Sangeeta Hingorani; Laura S Finn; Emily Pao; Rick Lawler; Gary Schoch; George B McDonald; Behzad Najafian; Brenda Sandmaier; Ted Gooley
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-11       Impact factor: 8.237

Review 8.  Clinical applications for biomarkers of acute and chronic graft-versus-host disease.

Authors:  John E Levine; Sophie Paczesny; Stefanie Sarantopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

9.  Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment.

Authors:  George B McDonald; Laura Tabellini; Barry E Storer; Richard L Lawler; Paul J Martin; John A Hansen
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

Review 10.  Opportunities and challenges of proteomics in pediatric patients: circulating biomarkers after hematopoietic stem cell transplantation as a successful example.

Authors:  Sophie Paczesny; Christine Duncan; David Jacobsohn; Robert Krance; Kathryn Leung; Paul Carpenter; Catherine Bollard; Jamie Renbarger; Kenneth Cooke
Journal:  Proteomics Clin Appl       Date:  2014-10-30       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.